Endothelial nitric oxide synthase regulation is altered in pancreas from cirrhotic rats

FROSSARD, Jean-Louis, et al.

Abstract

To determine whether biliary cirrhosis could induce pancreatic dysfunction such as modifications in endothelial nitric oxide synthase (eNOS) expression and whether the regulation of eNOS could be altered by the regulatory proteins caveolin and heat shock protein 90 (Hsp90), as well as by the modifications of calmodulin binding to eNOS.

Reference


PMID : 16482622
Endothelial nitric oxide synthase regulation is altered in pancreas from cirrhotic rats

Jean-Louis Frossard, Rafael Quadri, Antoine Hadengue, Philippe Morel, Catherine M Pastor

AIM: To determine whether biliary cirrhosis could induce pancreatic dysfunction such as modifications in endothelial nitric oxide synthase (eNOS) expression and whether the regulation of eNOS could be altered by the regulatory proteins caveolin and heat shock protein 90 (Hsp90), as well as by the modifications of calmodulin binding to eNOS.

METHODS: Immunoprecipitations and Western blotting analysis were performed in pancreas isolated from sham and cirrhotic rats.

RESULTS: Pancreatic injury was minor in cirrhotic rats but eNOS expression importantly decreased with the length (and the severity) of the disease. Because co-immunoprecipitation of eNOS with both Hsp90 and caveolin similarly decreased in cirrhotic rats, eNOS activity was not modified by this mechanism. In contrast, cirrhosis decreased the calmodulin binding to eNOS with a concomitant decrease in eNOS activity.

CONCLUSION: In biliary cirrhosis, pancreatic injury is minor but the pancreatic nitric oxide (NO) production is significantly decreased by two mechanisms: a decreased expression of the enzyme and a decreased binding of calmodulin to eNOS.

INTRODUCTION

Chronic bile duct ligation (BDL) in rats induces severe cirrhosis associated with extra-hepatic organ dysfunction in heart[1], lung[2-4], and extrahepatic vessels such as aorta[4-6] and mesenteric artery[6]. Chronic BDL also induces pulmonary injury associated with hypoxemia and pulmonary vasodilatation due to an excess production of endothelial nitric oxide (eNO)[6-9]. In aorta and mesenteric artery from BDL rats, hyporeactivity to vasoconstrictors also originates from NO overproduction[6-9]. Pancreas may suffer from hemodynamic consequences of cirrhosis, but information on eNOS expression and regulation in this splanchnic organ is missing.

In all types of cirrhotic livers, although eNOS protein expression is increased or decreased, the activity is uniformly decreased[7-10]. The reason for the decrease in hepatic NO bioavailability remains unclear. One explanation is that caveolin expression, a negative regulatory protein of eNOS, increases during cirrhosis and alters enzyme activity[10]. However, such negative post-translational regulation of eNOS is not unique.

In isolated endothelial cells, transcriptional and post-transcriptional mechanisms regulating eNOS have been described. although eNOS activity is associated with changes in Ca2+ concentrations within endothelial cells, increase in Ca2+ concentration alone is not sufficient to modify enzyme activity[11]. Binding of calmodulin (CaM) and flow of electrons from the reductase to the oxygenase domains of the enzyme are dependent on phosphorylation and dephosphorylation of various residues of eNOS. Additionally, proteins such as caveolin and heat shock protein 90 (Hsp90) associate with eNOS and modify the enzyme activity as well as its intracellular localization[12, 13]. eNOS is co-localized with regulatory proteins and other molecules of the signal transduction pathway to form an “eNOS signaling complex” that modulates NO production[11]. For example, eNOS co-localizes with kinases that phosphorylate eNOS on the Thr residue with a concomitant decrease in enzyme activity[14].

The aim of our study was to determine whether biliary cirrhosis could induce pancreatic dysfunction including...
were precipitated with protein G-sepharose beads (Sigma, Buchs, Switzerland). Complexes were washed twice in lysis buffer. The samples were boiled in loading buffer (Laemmli sample buffer, BioRad) to elute the bound proteins. Total or phosphorylated eNOS, Hsp90, caveolin and calmodulin were detected by Western blot. Antibodies used included mouse monoclonal anti-eNOS and rabbit polyclonal anti-caveolin-1 from BD Biosciences-Pharmingen (Basel, Switzerland), rat monoclonal anti-Hsp90 from Stressgen (Bioggio, Switzerland), mouse monoclonal anti-calmodulin from Upstate (Lake Placid, New York) and goat polyclonal anti-phospho-eNOS-Thr495 from Santa Cruz Biotechnology (Santa Cruz, California).

**RESULTS**

**Pancreatic injury and biliary cirrhosis**

Chronic bile duct ligation induced severe hepatic...
Figure 1 Pancreatic tissues from sham and BDL-60 rats were stained with hematoxylin and eosin (panels A and C) and Gomori (panels B and D). In panels A and C, magnification is 100x and 400x (upper: small vessel; middle: acini; lower: Langerhans islet) and in panels B and D, magnification is 400x. The extracellular matrix was enlarged in pancreas isolated from BDL-60 rats and most of the enlarged extracellular matrix consisted of edema. No increase in reticulin fibers was observed with the Gomori technique. n = 3 in each group.

Figure 2 Endothelial nitric oxide synthase (eNOS), heat shock protein 90(Hsp90), and caveolin expression in pancreatic lysates isolated from control (Ctrl), sham rats, and rats with bile duct ligation (BDL) 15, 30, and 60 days before tissue collection (left panel). Densitometry (right panels) was measured in ≥ 4 rats in each group.

Figure 3 Immunostaining of caveolin (I) in pancreas isolated from BDL-30 rat. Caveolin was detected in epithelial cells lining the pancreatic ductules (C), cells within the islets of Langerhans (D), and in the apex of acinar cells (B). Caveolin was also present in endothelial lining cells in veinules (A), microvessels surrounding acini (B), and microvessels inside Langerhans islets (D). Immunostaining of Hsp90 (II) in pancreas isolated from BDL-15 rat. Hsp90 was present in epithelial cells lining the pancreatic ductules (C), cells within the islets of Langerhans (D), and in the apex of acinar cells (B). Hsp90 was also present in endothelial lining cells in veinules (A). Immunostaining of endothelial nitric oxide synthase (III) in pancreas isolated from BDL-15 rat. The protein was present in endothelial lining cells (B) and cells within the islets of Langerhans (D). In aorta isolated from BDL-60 rats (A), eNOS is more heavily stained. Magnification is 400x.

Diseases as evidenced by the increase in serum bilirubin and aspartate aminotransferase concentrations (Table 1). In contrast, serum amylase concentration was
slightly increased only in rats with BDL 60 d before the experiment.

Pancreatic injury was minor in rats with BDL. On histological examinations, the only modification was the enlargement of the interstitial space in rats with BDL 60 days before the experiment (BDL-60 rats, Figure 1A). No pancreatic necrosis was observed at any time point. The enlarged extracellular matrix consisted of edema because reticulin fibers surrounding acini in sham rats did not increase in BDL-60 rats (Figure 1B).

**Expression of endothelial NO synthase and its regulatory proteins**

eNOS expression was significantly decreased in BDL-15, BDL-30 and BDL-60 rats ($P=0.003$).

The two regulatory proteins of eNOS, Hsp90 (positive regulatory protein of eNOS) and caveolin (negative regulatory protein of eNOS), had different evolution. Hsp90 expression was maintained at the beginning of the disease but significantly decreased in BDL-60 rats ($P=0.02$) while caveolin expression slightly decreased in BDL-15 rats but recovered in BDL-30 and BDL-60 rats ($P=0.05$) (Figure 2).

**Protein immunostaining**
The localization of caveolin in pancreas is illustrated in Figure 3. Caveolin was present in epithelial cells lining the pancreatic ductules, cells within the islets of Langerhans and in the apex of acinar cells. Caveolin was also present in endothelial lining cells in veins, microvessels surrounding acini and microvessels within Langerhans islets. Hsp90 was present in epithelial cells lining the pancreatic ductules, cells within the islets of Langerhans and in the apex of acinar cells. Hsp90 was also present in endothelial lining cells in veins. Immunostaining of eNOS was weak in comparison to caveolin and Hsp90. Endothelial NOS was present only in endothelial cells and cells within the islets of Langerhans. In aorta isolated from BDL-60 rats (used as positive controls), eNOS was more easily detected.

**Co-immunoprecipitation of eNOS, caveolin and Hsp90 in sham and BDL-15 rats**

Hsp90 and caveolin were co-immunoprecipitated with eNOS in pancreas isolated from sham and BDL-15 rats (Figure 4). Because in BDL-15 rats, the reduction in coimmunoprecipitation of Hsp90 and caveolin was similar to the decrease in eNOS expression ($P=0.74$), eNOS activity was not modified by this mechanism in BDL-15 rats. Co-immunoprecipitation from pancreas isolated from BDL-30 and BDL-60 rats was not available because the amount of eNOS protein in samples was too low.

**Calmodulin and 495Thr-P-eNOS expression**

In pancreatic lysates, 495Thr-P eNOS was not detectable.
at any time point, though the phosphorylated eNOS was easily detected in the liver (Figure 5).

Expression of CaM was evident and did not differ between groups \( (P = 0.95) \). In BDL-15 rats, the co-immunoprecipitation of eNOS with CaM decreased while 495-Thr-P eNOS became detectable.

Interestingly, the cGMP concentration in pancreatic tissue was slightly lower in BDL-15 rats than in sham rats (62 pmol/g vs 90 pmol/g protein, \( P = 0.086 \)).

**DISCUSSION**

Our study showed that pancreatic injury was mild in rats with chronic biliary cirrhosis. Nevertheless, the expression of eNOS importantly decreased with the duration (and the severity) of the disease. The regulation of eNOS by Hsp90 and caveolin was not modified by a 15-day BDL but cirrhosis decreased the CaM binding to eNOS with a concomitant phosphorylation of the enzyme on 495-Thr residue, suggesting that the activity of the enzyme decreases through this regulatory pathway. Consequently, besides liver, lungs and extrahepatic vessels, pancreas is another organ in which eNOS regulation is markedly impaired by cirrhosis.

**Chronic biliary cirrhosis**

BDL is frequently used to induce chronic biliary cirrhosis in rats. In this model, the severity of hepatic injury increases with the duration of BDL. This model is also characterized by extra-hepatic injuries. Chronic BDL is associated with severe cardiomyopathy\(^1\). Vasod constriction to phenylephrine or vasodilatation to acetylcholine decreases in large vessels such as aorta\(^3, 16, 17\), mesenteric\(^5\) and pulmonary arteries\(^6\). Additionally, the modifications observed in lungs from BDL rats mimic the hepatopulmonary syndrome that complicates human cirrhosis\(^3\). In the present study, we described for the first time a slight pancreatic injury that appeared only 2 months after BDL.

**BDL and eNOS expression**

Organ dysfunction during biliary cirrhosis includes modification in NO release. eNOS expression has been investigated in livers from normal and BDL rats and the expression is similar in control and BDL-24 rats\(^19\). Modifications in eNOS expression have also been found in extrahepatic organs isolated from rats with BDL. For example, in aortic rings isolated from BDL-28 rats, eNOS protein expression is increased. For example, in aortic rings isolated from BDL-28 rats, eNOS protein expression is increased\(^20\). These results have been confirmed in rats sacrificed at different time points (BDL-21 and BDL-30 rats)\(^18, 21\). The expression of eNOS in pulmonary arteries isolated from BDL-28 rats is also increased\(^18, 21\). The high staining of eNOS observed in aorta isolated from BDL-60 rats (Figure 3) might confirm these findings.

In our study, we used the BDL model of cirrhosis. However, additional experimental models exist, including chronic ingestion of CCl4 that also shows a dysregulation of eNOS\(^8\). Though BDL rats develop hepatic cirrhosis with systemic vasodilatation and hepatopulmonary syndrome as observed in humans\(^9\), the results obtained in BDL rats should be extrapolated to humans with caution.

eNOS has already been detected in normal pancreas\(^23-25\). For the first time, we showed that eNOS expression significantly decreased in pancreas collected from BDL-15 rats with a further decrease associated with the duration of bile duct ligation. Interestingly, we localized eNOS in endothelial cells and cells within the islets of Langerhans. However, the staining was weak, suggesting that eNOS has a low expression in native pancreas.

**eNOS regulation in native tissues**

The regulation of eNOS is a process determined by a cascade of events, including changes in (1) NOS mRNA and protein levels, (2) association of eNOS with regulatory proteins in the signaling complex, (3) changes in intracellular location of the enzyme and (4) phosphorylation of serine, threonine and tyrosine residues. Though many of these steps have been relatively well elucidated in in vitro models and in cell lines overexpressing one or more components of the signaling complex, much more work is required to determine which modification plays a dominant role in the regulation of eNOS activity in native tissues.

In our experimental study, the two regulatory proteins of eNOS, Hsp90 and caveolin, had a different evolution. Caveolin expression slightly decreased in BDL-15 rats but recovered in BDL-30 and BDL-60 rats. The reason for the transient decrease is unclear. In contrast, in livers from BDL rats, caveolin expression increases\(^29\). In normal pancreas, caveolin is detectable in membrane preparations\(^20\). Caveolin-1 has been identified in exocrine cells and secretagogues known to stimulate secretions in exocrine cells also release caveolin\(^27\). However, the function of secreted caveolin in pancreas is unknown. We also identified caveolin in epithelial cells lining the pancreatic ductules, cells within the islets of Langerhans, and endothelial cells lining veins, microvessels surrounding acini and inside Langerhans islets.

In our study, Hsp90 expression was maintained at the beginning of the disease but significantly decreased in BDL-60 rats. Hsp90 is constitutively expressed at high concentration in normal pancreas and the expression does not increase during acute pancreatitis\(^28\) or hyperthermia\(^29, 30\). In the present study, we showed for the first time, the localization of Hsp90 in epithelial cells lining the pancreatic ductules, cells within the islets of Langerhans, acinar cells and endothelial cells in veins.

In BDL livers, co-immunoprecipitation of caveolin with eNOS increases and this binding is associated with a decreased eNOS activity\(^10\). Co-immunoprecipitation of Hsp90 with eNOS was not investigated in this study. In pancreas from BDL-15 rats, the co-immunoprecipitation of eNOS with both caveolin and Hsp90 similarly decreased, suggesting that the two regulatory proteins have no effect on pancreatic eNOS activity.

**Co-immunoprecipitation of eNOS with CaM and eNOS phosphorylation on Thr residue**

Phosphorylation of eNOS on the 495-Thr residue in isolated endothelial cells is associated with a decrease in enzyme...
activity. The link between phosphorylation and NO production can be explained by the interference with the binding of CaM to the CaM-binding domain of eNOS [11, 14, 15]. Changes in $^{495}$Thr phosphorylation are generally associated with stimuli such as bradykinin, histamine and Ca$^{2+}$ ionophores. In endothelial cells, these Ca$^{2+}$ elevating agonists decrease $^{495}$Thr phosphorylation of eNOS with a concomitant increased binding of CaM to the CaM-binding site of eNOS.

Interestingly, we showed a similar regulatory mechanism induced by cirrhosis in native pancreas. The $^{495}$Thr-phosphorylated form of eNOS undetectable in normal pancreas (in contrast to normal liver) appeared in pancreas from cirrhotic rats. Concomitantly, the increased expression of $^{495}$Thr-P-eNOS was associated with a decreased binding of CaM to eNOS.

Besides the regulatory proteins and CaM, other proteins are likely to interfere with the regulation of eNOS in the pancreas$^{11}$. Phosphorylation of $^{1178}$Ser is another well-identified mechanism activating the enzyme. These regulatory pathways and probably many others concomitantly modify eNOS activity. Although we found a decreased cGMP concentration in pancreas from BDL-15 rats, the numerous pathways regulating eNOS preclude the modifications of eNOS activity to the decreased binding of CaM.

In conclusion, co-immunoprecipitation of Hsp90 and caveolin with eNOS has no effect on eNOS activity while the binding of CaM to eNOS decreases with a likely concomitant decrease in eNOS activity. Besides liver, lungs and extra-hepatic vessels, pancreas is another organ with its eNOS expression modified by cirrhosis.

REFERENCES


8 Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. *Gastroenterology* 1998; 114: 344-351


10 Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. *Am J Physiol Gastrointest Liver Physiol* 2001; 280: G1209-G1216


12 Balligand JL. Heat shock protein 90 in endothelial nitric oxide synthase signaling: following the lead(e)r? *Circ Res* 2002; 90: 838-841


14 Venema RC. Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. *Int Immunopharmacol* 2002; 2: 1755-1762


